

# **The targets and role of palmitoylation in *Plasmodium* parasites**

---

**Chwen Ling Tay (BSc Hons)**

**Christ's College, University of Cambridge  
Wellcome Trust Sanger Institute**

**This dissertation is submitted for the degree of  
Doctor of Philosophy in Biological Science**

This dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration except where specifically stated in the text.

This dissertation does not exceed the word limit of 60000 words for the Degree Committee for the Faculty of Biology.

## **Abstract**

Palmitoylation is the post-translational reversible addition of the acyl moiety, palmitate, to cysteine residues of proteins, and has been shown to be important in regulating protein trafficking, localisation, stability and function. Palmitoylation is wide-spread in all eukaryotes, and recent work revealed the presence of more than 400 palmitoylated proteins in the *Plasmodium falciparum* intraerythrocytic schizont stages, including proteins involved in key aspects of malaria biology and pathogenesis. The work described in this dissertation advances our understanding of protein palmitoylation in *Plasmodium* by developing a novel method to specifically identify palmitoylated cysteines within the *P. falciparum* palmitome, and characterising for the first time, the *Plasmodium* DHHC and MBOAT proteins, which are thought to mediate protein palmitoylation.

In the first section of work, a quantitative mass spectrometry based approach was developed to identify palmitoylation sites, resulting in the identification of over 100 putative palmitoylation sites in the *P. falciparum* schizont palmitome. These potential palmitoylation sites can be used to guide further experiments into the role of palmitoylation in the function of specific proteins. Pilot experiments were also carried out with related parasites, *P. berghei* and *Toxoplasma gondii*, and revealed palmitoylation sites that were conserved across Apicomplexan species.

The *Plasmodium* DHHC protein family was characterised in *P. falciparum* and *P. berghei*, establishing that individual DHHC proteins are localised to distinct organelles, including specialised parasite-specific organelles such as the rhoptries and the IMC. DHHC protein localisation may therefore play some role in substrate specificity. Knock-out studies identified individual DHHC proteins that were essential for blood stage growth, as well as proteins that could be successfully disrupted, suggesting that a subset of DHHCs is functionally redundant. Lastly, an assay was developed to demonstrate the palmitoyl transferase activity of the *Plasmodium* DHHC proteins, confirming for the first time that these proteins are responsible for protein palmitoylation in *Plasmodium* parasites. This assay further revealed that different *P. falciparum* DHHC proteins could palmitoylate the same target protein, further confirming the existence of overlapping functionality for these proteins in *Plasmodium*.

The occurrence of palmitoylation on so many *Plasmodium* proteins, as well as the existence of a repertoire of *Plasmodium* proteins shown to demonstrate palmitoyl transferase activity, indicate that this post-translational modification may have an important role in the normal cellular function of the parasite. Further study of palmitoylation in *Plasmodium* may thus result in the discovery of potential therapeutic drug targets, and the assays developed here could assist in achieving this goal.

## **Acknowledgements**

First and foremost, sincere thanks to Julian Rayner for excellent guidance and supervision during this entire PhD, as well as for careful reading of this dissertation. Special thanks also to Matt Jones for teaching, advice, discussion and assistance in all things. Many thanks also to Mark Collins for all the hard work on the site-ID purification protocol and mass spectrometry. Thanks also to Michel Theron for kind assistance in designing the *P. falciparum* growth assay and for the flow cytometry analysis, as well as to Leyla Bustamente for qPCR analysis. Thanks also to Ellen Bushell for the generation of *P. berghei* transgenic strains and PFGE analysis. All your time and effort is greatly appreciated.

## Table of Contents

<b>Abstract</b>	<b>1</b>
<b>Acknowledgements</b>	<b>2</b>
<b>Table of Contents</b>	<b>3</b>
<b>List of Abbreviations</b>	<b>5</b>
<b>List of Figures</b>	<b>8</b>
<b>List of Tables</b>	<b>10</b>
<b>Chapter 1: Introduction</b>	<b>11</b>
1.1. Protein palmitoylation: Definition	11
1.2. Protein acyltransferases (PATs)	12
1.3. Acyl-protein thioesterases	15
1.4. Functions of protein palmitoylation	16
1.5. Types of palmitoylated proteins	19
1.6. Purification of palmitoylated proteins	21
1.7. Malaria: A major global parasitic disease	25
1.8. The life cycle of <i>Plasmodium</i> parasites	26
1.9. The need for new drug targets	29
1.10. Palmitoylation in <i>Plasmodium</i>	29
1.11. Aims and objectives	32
<b>Chapter 2: Materials and Methods</b>	<b>37</b>
2.1. Generation of plasmid constructs	37
2.2. <i>Plasmodium in vitro</i> cell culture and transfection	43
2.3 Genotyping of transgenic parasite strains	47
2.4. Human Embryonic Kidney 293 (HEK293) <i>in vitro</i> cell culture and transfection	50
2.5. Protein detection and analysis	51
2.6. Palmitome purification in <i>P. falciparum</i> parasites and HEK293 cells	53
<b>Chapter 3: The sites of palmitoylation in the <i>Plasmodium falciparum</i> palmitome</b>	<b>58</b>
3.1. Development of the site-identification (ID) palmitome purification method	58
3.2. Analysis of the overlaps between the five trial site-ID palmitome purifications	82
3.3. Trial site-ID palmitome purification from <i>Plasmodium berghei</i> schizonts and <i>Toxoplasma gondii</i> tachyzoites	95
<b>Chapter 4: Protein acyltransferases in <i>Plasmodium berghei</i></b>	<b>103</b>

4.1. Repertoire of DHHC-domain-containing proteins in <i>Plasmodium</i>	103
4.2. Expression and localisation of DHHC proteins in <i>Plasmodium berghei</i>	106
4.3. Essentiality of the DHHC proteins in <i>P. berghei</i>	114
<b>Chapter 5: Protein acyltransferases in <i>Plasmodium falciparum</i></b>	<b>117</b>
5.1. Expression and localisation of DHHC and MBOAT proteins in <i>Plasmodium falciparum</i>	117
5.2. Essentiality of DHHC and MBOAT proteins in <i>P. falciparum</i>	128
<b>Chapter 6: Protein acyltransferase activity of <i>Plasmodium falciparum</i> DHHC proteins</b>	<b>142</b>
6.1. PAT activity assay – the method	142
6.2. Expression and localisation of <i>P. falciparum</i> proteins in HEK293 cells	145
6.3. PAT activity assay of PfDHHC proteins with PfSec22 and PfARO	153
6.4. Point mutations of potential palmitoylation sites in PfSec22 and PfARO	160
6.5. Site-directed mutagenesis of the cysteine in the DHHC domain of PfDHHC5	163
<b>Chapter 7: Discussion</b>	<b>169</b>

## **List of Abbreviations**

2-BMP – 2-bromopalmitate

3-HA – triple-haemagglutinin

5FC – 5-fluorocytosine

6-FAM – 6-carboxyfluorescein

17-ODYA – 17-octadecynoic acid

ABE – Acyl-biotinyl exchange

AMPA –  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole propionate

APT – Acyl-protein thioesterase

ARO – Armadillo repeats-only

$\beta$ -ME –  $\beta$ -mercaptoethanol

BSA – Bovine serum albumin

CDPK1 – Calcium-dependent protein kinase 1

CRT – Chloroquine resistance transporter

DGAT – Diacylglycerol acyltransferase

DHHC – Aspartate-Histidine-Histidine-Cysteine

DMSO – Dimethyl sulphoxide

eNOS – Endothelial nitric oxide synthase

ER – Endoplasmic reticulum

FBS – Foetal bovine serum

GAP45 – Glideosome-associated protein 45

GO – Gene ontology

GPI – glycosylphosphatidylinositol

HEK293 – Human embryonic kidney 293

Hh – Hedgehog

Hhat – Hedgehog acyltransferase

HRP – Horse radish peroxidase

IAA - Iodoacetamide

IMC – Inner membrane complex

KAHRP – Knob-associated histidine-rich protein

MBOAT – Membrane-bound O-acyl transferase

MESA – Mature-parasite-infected erythrocyte surface antigen

MSP1 – Merozoite surface protein 1

MTIP – myosin A tail domain-interacting protein

MWCO – Molecular weight cut-off

NEM – N-ethylmaleimide

PAT – Protein acyl transferase

PBS – Phosphate buffered saline

PBST – PBS with 0.1% Tween-20

PCR – Polymerase chain reaction

PEI – Polyethylenimine

PfEMP1 – *P. falciparum* erythrocyte membrane protein 1

PFGE – Pulsed field gel electrophoresis

PPT – Protein palmitoylthioesterase

PSD-95 – Post synaptic density protein-95

PTM – Post-translational modification

RAP1 – Rhoptry associated protein 1

RT-PCR – Reverse transcription-PCR

SDS – Sodium dodecyl sulphate

SDS-PAGE – SDS-polyacrylamide gel electrophoresis

Shh – Sonic Hedgehog

SILAC – Stable isotope labelling with amino acids in cell culture

SNARE – Soluble NSF attachment protein receptor



TBTA – Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine

TCEP – Tris(2-carboxyethyl)phosphine

TCR – T cell receptor

TM – Transmembrane

## List of Figures

<b>Figure 1.1:</b> Reversible S-palmitoylation compared to irreversible N-palmitoylation	<b>12</b>
<b>Figure 1.2:</b> Structure of DHHC-domain and MBOAT-domain-containing PATs	<b>15</b>
<b>Figure 1.3:</b> Function of palmitoylation on the subcellular trafficking of Ras proteins in mammalian cells	<b>17</b>
<b>Figure 1.4:</b> Schematic of the acyl-biotinyl exchange (ABE) method of purifying palmitoyl-proteins	<b>23</b>
<b>Figure 1.5:</b> Schematic of the metabolic labelling and click chemistry method of purifying palmitoyl-proteins	<b>24</b>
<b>Figure 1.6:</b> Schematic of the <i>Plasmodium</i> parasite's life cycle	<b>28</b>
<b>Figure 2.1:</b> Schematic of the <i>P. falciparum</i> and HEK293E expression plasmid constructs	<b>41</b>
<b>Figure 3.1:</b> Trial 1 site-ID palmitome purification by ABE	<b>63</b>
<b>Figure 3.2:</b> Trial 2 site-ID palmitome purification by ABE	<b>68</b>
<b>Figure 3.3:</b> Trial 3A site-ID palmitome purification by ABE	<b>71</b>
<b>Figure 3.4:</b> Trial 3B site-ID palmitome purification by ABE	<b>74</b>
<b>Figure 3.5:</b> Trial 4 site-ID palmitome purification by ABE	<b>77</b>
<b>Figure 3.6:</b> Overlaps between the different trial site-ID palmitome purifications and the total palmitome	<b>83</b>
<b>Figure 3.7:</b> Gene ontology (GO) term analysis of enriched proteins in the overlapping trial site-ID purification datasets	<b>86</b>
<b>Figure 3.8:</b> Over-represented sequence motifs within the Trial 4 site-ID palmitome purification dataset	<b>93</b>
<b>Figure 3.9:</b> Trial site-ID palmitome purification by ABE for <i>Plasmodium berghei</i> and <i>Toxoplasma gondii</i>	<b>96</b>
<b>Figure 4.1:</b> Repertoire of DHHC-containing proteins in <i>Plasmodium</i>	<b>105</b>
<b>Figure 4.2:</b> Generation of PbDHHC triple-HA-tagged and knock-out transgenic lines	<b>107</b>
<b>Figure 4.3:</b> Expression of PbDHHC proteins in purified <i>P. berghei</i> schizonts	<b>108</b>
<b>Figure 4.4:</b> Localisation of DHHC proteins in <i>P. berghei</i> schizonts	<b>111</b>
<b>Figure 5.1:</b> Generation of PfDHHC and PfMBOAT triple-HA-tagged transgenic lines	<b>119</b>
<b>Figure 5.2:</b> Expression of PfDHHC and PfMBOAT proteins in <i>P. falciparum</i> schizonts	<b>121</b>
<b>Figure 5.3:</b> Localisation of DHHC and MBOAT proteins in <i>P. falciparum</i>	<b>124</b>
<b>Figure 5.4:</b> Generation of PfDHHC and PfMBOAT knock-out transgenic lines in <i>P. falciparum</i>	<b>133</b>
<b>Figure 5.5:</b> Reverse transcription (RT)-PCR analysis of PfDHHC5-KO and PfDHHC9-KO transgenic lines	<b>136</b>
<b>Figure 5.6:</b> Growth assay comparing the growth of PfDHHC5-KO and PfDHHC9-KO with wild-type 3D7	<b>138</b>

<b>Figure 6.1:</b> PAT activity assay	<b>144</b>
<b>Figure 6.2:</b> Localisation of codon-optimised <i>P. falciparum</i> proteins in HEK293 cells	<b>150</b>
<b>Figure 6.3:</b> Immunoprecipitation of PfSec22 and PfARO proteins using antibodies against the c-Myc tag	<b>153</b>
<b>Figure 6.4:</b> PAT activity assay demonstrating the PAT activity of PfDHHC proteins on the target protein, PfSec22	<b>155</b>
<b>Figure 6.5:</b> PAT activity assay demonstrating the PAT activity of PfDHHC proteins on the target protein, PfARO	<b>158</b>
<b>Figure 6.6:</b> Immunoprecipitation of mutant PfSec22 and PfARO proteins using antibodies against the c-Myc tag	<b>162</b>
<b>Figure 6.7:</b> Immunoprecipitation of PfSec22 and PfARO proteins when co-expressed with mutant PfDHHC5 using antibodies against the c-Myc tag	<b>165</b>

## List of Tables

<b>Table 1.1:</b> Common classes of palmitoylated proteins	<b>20</b>
<b>Table 2.1:</b> Primers used for the generation of <i>P. falciparum</i> triple-HA-tagged plasmid Constructs	<b>38</b>
<b>Table 2.2:</b> Primers used for the generation of <i>P. falciparum</i> double-crossover knock-out plasmid constructs	<b>39</b>
<b>Table 2.3:</b> PlasmogEM vectors used for the generation of 3HA-tagged and knock-out transgenic strains in <i>P. berghei</i>	<b>40</b>
<b>Table 2.4:</b> Primers used for the generation of point mutations in HEK293 expression plasmid constructs	<b>43</b>
<b>Table 2.5:</b> Primers used for the genotyping of <i>P. falciparum</i> triple-HA-tagged lines	<b>47</b>
<b>Table 2.6:</b> Primers used for the genotyping of <i>P. falciparum</i> knock-out lines	<b>48</b>
<b>Table 2.7:</b> Primers used for the PCR analysis of the cDNA of PfDHHC5-KO and PfDHHC9-KO transgenic clones	<b>49</b>
<b>Table 2.8:</b> Primers and probes used for the qPCR analysis of the cDNA of PfDHHC5-KO and PfDHHC9-KO transgenic clones	<b>50</b>
<b>Table 2.9:</b> All primary and secondary antibodies used in this work along with their appropriate working dilutions	<b>51</b>
<b>Table 3.1:</b> Summary of all five trial site-ID purifications and the analyses performed on the five datasets	<b>81</b>
<b>Table 3.2:</b> The 14 enriched peptides identified in all 4 trial site-ID palmitome purifications	<b>84</b>
<b>Table 3.3:</b> A selected set of enriched proteins found to be common between both label-free trial site-ID datasets (Trial 3B and Trial 4), as well as the total palmitome, along with a selected set of enriched peptides common between both the trial datasets	<b>88</b>
<b>Table 3.4:</b> A selected set of enriched proteins found to be common between the Trial 4 site-ID dataset and the total palmitome, along with a selected set of corresponding enriched peptides	<b>91</b>
<b>Table 3.5:</b> Summary of the analyses performed on the overlaps between the different trial site-ID palmitome purifications	<b>94</b>
<b>Table 3.6:</b> Summary of the trial site-ID purifications for <i>P. berghei</i> and <i>T. gondii</i> , and the analyses performed on the two datasets	<b>97</b>
<b>Table 3.7:</b> A selected set of enriched proteins purified in the <i>P. berghei</i> trial site-ID palmitome purification, along with their <i>P. falciparum</i> homologues, present in the <i>P. falciparum</i> Trial 4 site-ID palmitome purification	<b>98</b>
<b>Table 3.8:</b> A selected set of enriched proteins purified in the <i>T. gondii</i> trial site-ID palmitome purification, along with their <i>P. falciparum</i> homologues (homologues were determined by protein-protein BLAST search) found to be present in the <i>P. falciparum</i> Trial 4 site-ID palmitome purification	<b>100</b>
<b>Table 4.1:</b> DHHC-domain-containing proteins in <i>Plasmodium berghei</i> and <i>Plasmodium Falciparum</i>	<b>104</b>